Design, Synthesis, and Anticancer Evaluation of Hemithioindigos via Inhibition of Human Topoisomerases

dc.contributor.authorKaur, Manpreet
dc.contributor.authorSuman, Prabhat
dc.contributor.authorArora, Sahil
dc.contributor.authorSingh, Tashvinder
dc.contributor.authorMunshi, Anjana
dc.contributor.authorSingh, Sandeep
dc.contributor.authorKumar, Raj
dc.date.accessioned2024-01-21T10:54:20Z
dc.date.accessioned2024-08-14T07:41:04Z
dc.date.available2024-01-21T10:54:20Z
dc.date.available2024-08-14T07:41:04Z
dc.date.issued2023-11-06T00:00:00
dc.description.abstractHemithioindigos were designed as topoisomerase inhibitors, synthesized, and evaluated for their anticancer properties against lung (A549) and breast (MDA-MB-468 and MCF7) cancer cell lines. Among all the synthetics, three compounds exerted potential anticancer effects on A549 (lung) and MCF7 (breast) cancer cell lines at low micromolar concentrations. The results revealed that two of these compounds blocked the cancer cells at the G1/S phase, while the third compound showed moderate G2/M inhibition, leading to necrotic cell death. Finally, the topoisomerase inhibition assays revealed their potent Topo I/II inhibitory actions as one of the primary anticancer mechanisms. Molecular docking studies further corroborated these findings. � 2023 Wiley-VCH GmbH.en_US
dc.identifier.doi10.1002/slct.202301700
dc.identifier.issn23656549
dc.identifier.urihttp://10.2.3.109/handle/32116/4280
dc.identifier.urlhttps://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202301700
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.subject2-Arylidenebenzo[b]thiophen-3(2H)-onesen_US
dc.subjectAnticancer agentsen_US
dc.subjectHemithioindigosen_US
dc.subjectMolecular dockingen_US
dc.subjectTopoisomerase inhibitorsen_US
dc.titleDesign, Synthesis, and Anticancer Evaluation of Hemithioindigos via Inhibition of Human Topoisomerasesen_US
dc.title.journalChemistrySelecten_US
dc.typeArticleen_US
dc.type.accesstypeClosed Accessen_US

Files